Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 - Research and Markets

Research and Markets
Posted on: 25 Aug 16

Research and Markets has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025" report to their offering.

The report "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025" examines the leaders in the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions.

For each company covered, the report provides:

  • Corporate Summary
  • Total Company Revenue and Total R&D Spending 2011-2015
  • Break-up of Sales by Region, 2015
  • Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025
  • Leading Pharmaceutical Products, 2015 Sales
  • Late Stage Product Pipeline
  • Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015
  • Corporate Development Details

The companies covered in this study include:

  • Pfizer
  • Novartis
  • Roche
  • Merck
  • Sanofi and 20 more

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 provides a thorough discussion of current trends in pharmaceutical research and development, including:

  • Pharmaceutical Research & Development Challenge
  • The Drug Approval Process
  • Expanded Options in Treating Diseases
  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • The Role of Contract Research Organizations

In addition to its company focus, the report examines the global pharmaceutical market, which has continued its recovery from the economic downfall experienced in recent years. Healthcare costs as a percent of GDP are increasing in almost all countries, though there are some exceptions. There are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more.

Data provided include:

  • Global Pharmaceutical Projects in Development by Therapeutic Segment
  • Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
  • Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
  • Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates (Australia, Austria, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Japan, Mexico, Switzerland, United Kingdom, United States)
  • International Population Trend Age 65+

For more information about this report visit

Related Topics: Pharmaceuticals

View source version on

Business Wire

Last updated on: 25/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.